Jung Sun Kim1, Soyeon Kim2,3, Jaemoon Koh4, Miso Kim1,2, Bhumsuk Keam1,2, Tae Min Kim1,2, Bertil Lindmark5, Dong-Wan Kim6,7,8. 1. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. 2. Cancer Research and Institute, Seoul National University, Seoul, Republic of Korea. 3. Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea. 4. Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea. 5. Galecto, Inc., Copenhagen, Denmark. 6. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. kimdw@snu.ac.kr. 7. Cancer Research and Institute, Seoul National University, Seoul, Republic of Korea. kimdw@snu.ac.kr. 8. Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea. kimdw@snu.ac.kr.
Abstract
PURPOSE: We aimed to assess the predictive value of galectin-3 (Gal-3) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint blockades (ICBs) therapy using both enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC). METHODS: This retrospective study was conducted at Seoul National University Hospital. Patients with EGFR/ALK-wild-type advanced or metastatic NSCLC who received ICBs between December 2013 and December 2019 were enrolled. Patients with archived blood samples collected prior to ICB treatment were assigned to the ELISA cohort. In addition, those with tissue samples from sites of recurrence or metastasis were assigned to an IHC cohort. Then, we analyzed Gal-3 expression in both cohorts. RESULTS: Fifty-six patients in the ELISA cohort were grouped into low (N = 36) and high (N = 20) groups, using the mean Gal-3 ELISA level (13.24 pg/ml) as a cutoff. The high group demonstrated trends toward reduced progression-free survival (PFS) (0.9 vs. 3.7 months, p = 0.196) and significantly shorter overall survival (OS) (1.6 vs. 12.3 months, p = 0.018) than the low group. We categorized 94 patients in the IHC cohort into negative (N = 31) and positive (N = 63) groups based on Gal-3 IHC positivity. However, the median PFS (4.6 vs. 4.6 months for the negative vs. positive IHC group, respectively, p = 0.345) and OS (16.4 vs. 9.0 months, p = 0.137) were not significantly different. CONCLUSION: High blood Gal-3 levels may predict inferior survival in patients with advanced or metastatic NSCLC treated with ICBs.
PURPOSE: We aimed to assess the predictive value of galectin-3 (Gal-3) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint blockades (ICBs) therapy using both enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC). METHODS: This retrospective study was conducted at Seoul National University Hospital. Patients with EGFR/ALK-wild-type advanced or metastatic NSCLC who received ICBs between December 2013 and December 2019 were enrolled. Patients with archived blood samples collected prior to ICB treatment were assigned to the ELISA cohort. In addition, those with tissue samples from sites of recurrence or metastasis were assigned to an IHC cohort. Then, we analyzed Gal-3 expression in both cohorts. RESULTS: Fifty-six patients in the ELISA cohort were grouped into low (N = 36) and high (N = 20) groups, using the mean Gal-3 ELISA level (13.24 pg/ml) as a cutoff. The high group demonstrated trends toward reduced progression-free survival (PFS) (0.9 vs. 3.7 months, p = 0.196) and significantly shorter overall survival (OS) (1.6 vs. 12.3 months, p = 0.018) than the low group. We categorized 94 patients in the IHC cohort into negative (N = 31) and positive (N = 63) groups based on Gal-3 IHC positivity. However, the median PFS (4.6 vs. 4.6 months for the negative vs. positive IHC group, respectively, p = 0.345) and OS (16.4 vs. 9.0 months, p = 0.137) were not significantly different. CONCLUSION: High blood Gal-3 levels may predict inferior survival in patients with advanced or metastatic NSCLC treated with ICBs.
Authors: E J Aguilar; B Ricciuti; J F Gainor; K L Kehl; S Kravets; S Dahlberg; M Nishino; L M Sholl; A Adeni; S Subegdjo; S Khosrowjerdi; R M Peterson; S Digumarthy; C Liu; J Sauter; H Rizvi; K C Arbour; B W Carter; J V Heymach; M Altan; M D Hellmann; M M Awad Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Brendan D Curti; Yoshinobu Koguchi; Rom S Leidner; Annah S Rolig; Elizabeth R Sturgill; Zhaoyu Sun; Yaping Wu; Venkatesh Rajamanickam; Brady Bernard; Ian Hilgart-Martiszus; Christopher B Fountain; George Morris; Noriko Iwamoto; Takashi Shimada; ShuChing Chang; Peter G Traber; Eliezer Zomer; J Rex Horton; Harold Shlevin; William L Redmond Journal: J Immunother Cancer Date: 2021-04 Impact factor: 13.751